Sensitivity to somatomotor conflicts links frontal subcortical dysfunction and minor hallucinations in Parkinson's disease

Authors:

Jevita Potheegadoo, PhD[1*], Léa F. Duong Phan Thanh, MSc[1], Marie E. Maradan-Gachet MSc[2,3], Cyrille Stucker, MSc[1], Nathalie H. Meyer, PhD[1], Fosco Bernasconi, PhD[1], Laurent Jenni, MSc[1], Julien F. Bally, MD[4], Mayte Castro Jimenez, MD[4], Vanessa Fleury-Nissen, MD[5], Judit Horvath, MD[6], Benoît Wicki, MD[7], Javier Pagonabarraga Mora, MD, PhD[8], Paul Krack, MD[2], & Olaf Blanke, MD[1,9*].

Affiliation:

[1]Laboratory of Cognitive Neuroscience, Neuro-X Institute, School of Life Sciences, École Polytechnique Fédérale de Lausanne, EPFL, Geneva, Switzerland.

[2] Department of Neurology, Inselspital, University Hospital Bern, University of Bern, Bern, Switzerland.

[3] Graduate School for Health Sciences, University of Bern, Bern, Switzerland

[4] Department of Clinical Neurosciences, Service of Neurology, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.

[5] Department of Neurology, Geneva University Hospital, Geneva, Switzerland.

[6] Neurology Center, La Tour Hospital, Meyrin, Switzerland.

[7] Neurocentre, Hôpital du Valais, Sion, Switzerland.

[8] Movement Disorder Unit, Neurology Department, Hospital de la Santa Creu i Sant Pau, Barcelona, Department of Medicine, Autonomous University of Barcelona, Spain.

[9] Department of Clinical Neurosciences, University Hospital Geneva, Geneva, Switzerland.

Correspondence to:

Prof. Olaf Blanke

Laboratory of Cognitive Neuroscience

Bertarelli Foundation Chair in Cognitive Neuroprosthetics

Neuro-X Institute, Campus Biotech

Chemin des Mines 9,

1202 Geneva

Switzerland

+41 21 693 96 21

olaf.blanke@epfl.ch

Dr. Jevita Potheegadoo

Laboratory of Cognitive Neuroscience

Neuro-X Institute, Campus Biotech,

Chemin des Mines 9,

1202 Geneva

Switzerland

+41 21 693 95 68

jevita.potheegadoo@epfl.ch

Running title: Neuropsychological correlates of induced MH in PD

Financial disclosure/conflict of interest: OB is inventor on patent US 10,286,555 B2 (Title: Robot-controlled induction of the feeling of a presence) held by the Swiss Federal Institute (EPFL) that covers the robot-controlled induction of presence hallucinations. OB is inventor on patent US 10,349,899 B2 (Title: System and method for predicting hallucinations) held by the Swiss Federal Institute (EPFL) that covers a robotic system for the prediction of hallucinations for diagnostic and therapeutic purposes. OB is cofounder and shareholder of Metaphysiks Engineering SA. OB is member of the board and shareholder of Mindmaze SA. OB, JP and FB are inventors on patent n° EP24706201.1 (Title: Numerosity estimation impairment measurement system) held by the Swiss Federal Institute (EPFL) that covers the implicit measure of presence hallucinations.

Funding sources: This project was supported by two generous donors advised by CARIGEST SA, the first one wishing to remain anonymous and second one being *Fondazione Teofilo Rossi di Montelera e di Premuda*; the Bertarelli Foundation; Parkinson Schweiz, Leenaards foundation, Empiris foundation, Swiss National Science foundation, Synapsis Foundation.

Abstract

Background: Minor hallucinations (MH) affect 30-60% of patients with Parkinson's disease (PD), and are considered precursors to structured visual hallucinations and cognitive decline. While the link between structured visual hallucinations and dementia is well established, the neuropsychological correlates of MH in PD remain unclear, with most studies finding no significant cognitive differences between patients with MH and those without any hallucinations.

Objectives: Presence hallucinations (PH) being among the most prevalent MH in PD, we used a technological approach to experimentally induce PH to investigate whether sensitivity to such robot-induced PH aids in detecting cognitive differences between patients with MH and without hallucinations.

Methods: Twenty-five PD patients with MH (PD-MH) and 25 without hallucinations (PD-nH) underwent a comprehensive neuropsychological assessment and a robotic somatomotor procedure that is able to induce PH. The sensitivity to report robot-induced PH was analyzed in relation to the cognitive performance in neuropsychological tests.

Results: PD-MH patients reported more robot-induced PH than PD-nH patients, supporting previous findings. While both groups showed comparable performance in the different cognitive domains, we found a significant association between increased sensitivity to the PH-induction and poorer performance in frontal subcortical functions (executive functions), in PD-MH patients.

Conclusions: These findings demonstrate that sensitivity to robot-induced PH reveals a previously undetected link between MH and frontal subcortical cognitive deficits in PD, pointing to shared underlying mechanisms between executive dysfunction and somatomotor processing. This approach offers a novel and clinically valuable means of identifying early cognitive vulnerability that standard assessments may overlook.

Introduction

Hallucinations are common and frequent non-motor symptoms of Parkinson's disease (PD), affecting 30-60% of patients (1–3). Hallucinations in PD can manifest across different sensory modalities and vary in their phenomenological complexity (4,5). Typically, structured or well-formed hallucinations, which are primarily visual in PD (e.g., seeing people, animals, objects), emerge in the mid to advanced stages of the disease (6). However, many PD patients also experience so called "minor hallucinations" (MH) that occur frequently and earlier in the course of the illness, and precede structured visual hallucinations by many years and later co-occur with them (4,6–8). MH comprise presence hallucinations (PH) (sensation that someone is nearby despite no one being there), passage hallucinations (feeling of an indefinite figure passing in peripheral vision) and illusions (misperception of actual stimuli) (4). Both structured hallucinations and MH can cause significant distress, negatively affecting patients' quality of life, leading to increased caregiver burden, and complicating disease management with poor functional outcome (9–12). Moreover, several clinical and research findings highlighted that hallucinations represent a risk factor for accelerated cognitive decline and dementia in PD, suggesting a more severe or rapidly progressing form of the disease (13–15).

Cognitive deficits in PD can be viewed as a spectrum ranging from subtle cognitive changes and fluctuations to mild cognitive impairment and ultimately, dementia (14,16–18). Generally, PD patients can show deficits across multiple cognitive domains, including attention, visual and verbal memory, visuospatial abilities, and executive functions (19–22). Neuropsychological studies have consistently linked cognitive impairment and dementia to structured visual hallucinations, typical of advanced PD (8,13,23–27). Non-demented patients with structured visual hallucinations often show mild cognitive impairment with significant deficits in frontal subcortical functions such as executive functions, attention and visuospatial abilities (28–32). Research also indicated a sharp decline in posterior cortical functions (visual and spatial processing, language) during the transition to dementia in patients with visual hallucinations (8,27,30).

While MH are considered precursors to structured visual hallucinations and therefore a potential early marker of dementia (4,33), MH have not been linked to global cognitive decline nor dysfunction in specific cognitive domains using neuropsychological tests, despite evidence of structural and functional brain changes in PD patients with MH (34–36). Though a few studies suggested impairments of attentional control and visuospatial abilities in PD patients with MH compared to patients without hallucination (37,38), the large majority of studies did not find any significant differences in global or specific cognitive functions between PD patients with MH compared to patients without hallucination, with both groups having similar neuropsychological performance (32–34).

We recently described a method to experimentally induce MH, particularly PH, using robotically-controlled somatomotor stimulation (robot-induced PH, riPH) (39). This transitory controlled state of riPH has been studied in healthy and clinical populations, including PD (36,40–43), and found that PD patients with MH in daily life reported stronger riPH (i.e., were more sensitive) compared to PD patients without any hallucinations (36). Here, we examined cognitive function and riPH in a group of PD patients with MH (PD-MH) and without any hallucination (PD-nH). Based on our previous findings (36), we hypothesized that our PD-MH group would exhibit heightened sensitivity to riPH compared to the PD-nH group. Based on previous work (7,34,38,44), we did not expect significant differences in overall neuropsychological performance between the two groups as measured by a comprehensive neuropsychological test battery. Because riPH activate frontal brain regions (inferior frontal gyrus and premotor cortex) (36), we explored whether, in PD-MH patients, greater sensitivity to riPH would be associated with poorer frontal subcortical functioning (e.g., executive functions including resistance to interference, mental flexibility, inhibitory control) (37,38), but not with posterior cortical functions, which are more indicative of advanced cognitive decline (8,30). If confirmed, this would not only support the idea that the occurrence of MH in PD reflects frontal vulnerability, as hypothesized in previous work (7,37,38,45), but also highlight the value of riPH in combination with neuropsychological testing.

Methods

Participants and clinical assessment

Fifty outpatients (15 women) diagnosed with PD by neurologists, specialists in movement disorders, based on the United Kingdom Parkinson's Disease Society Brain Bank criteria (46), were included in the study. Experienced neuropsychologists conducted a semi-structured clinical interview to assess the occurrence and types of hallucinations in all patients. Those who experienced at least one MH recurrently, since disease onset and/or within the past month prior inclusion to the study, were classified as the PD-MH group (n=25), while those without any hallucination were categorized as the PD-nH group (n=25). The recruitment of patients was part of a larger multicenter project investigating hallucinations in PD. For the present study, given the primary focus on MH, patients experiencing structured visual hallucinations in addition to MH were not included. Socio-demographic and clinical data, including age, sex, disease duration, and levodopa equivalent daily dose (LEDD), were recorded. Severity of motor and non-motor symptoms of PD and stage of illness were evaluated using MDS-UPDRS and Hoehn and Yahr scales, respectively (47). State of anxiety and depression were assessed with the Hospital Anxiety and Depression scale (48). TABLE 1 summarizes the demographic and clinical characteristics of patients.

Patients were not diagnosed with other neurological, psychiatric, or substance abuse disorders. Written informed consent was obtained from all patients, and the study was approved by Swiss cantonal ethics committees (protocol reference 2019-02275), in accordance with the Declaration of Helsinki.

Neuropsychological assessment

All patients were screened for cognitive impairments with the Montreal Cognitive Assessment (MoCA) (49), followed by a comprehensive assessment of major cognitive domains such as executive functions, attention, visuospatial abilities, memory and language using the

Parkinson's Disease Cognitive Rating Scale (PD-CRS) (30). The PD-CRS consists of cognitive tests that separately assess frontal-subcortical dysfunctions (frontal subcortical score) and temporal posterior cortical impairment (posterior cortical score). We also tested patients' performance in two other comprehensive neuropsychological tests on executive function: the Trail Making Test (TMT part A and B) (cognitive flexibility) (50) and the Stroop color-word test (resistance to interference, inhibitory control and cognitive flexibility) (51). Finally, we assessed subjective cognitive decline or complaints of patients in daily life by means of a short interview and question 1.1 of MDS-UPDRS ("over the past week have you had problems remembering things, following conversations, paying attention, thinking clearly, or finding your way around the house or in town?").

Somatomotor stimulation task inducing PH

The experimental paradigm involving the robotic system was performed as described in previous work (36,39,40,52). A commercial haptic interface (Phantom Omni, SensAble Technologies) was placed in front of the patients, and integrated with a custom-made three-degree-of-freedom robot positioned behind the patient (39,40). Patients were seated and equipped with a blindfold and headphones delivering constant white noise to isolate them from external distractions. Participants were instructed to perform back-and-forth movements using the robotic device placed in front of them, with the hand they felt most comfortable using. The hand movement performed by patients was reproduced by the other robotic device located behind them, delivering tactile feedback on the participants' back (see **FIG. 1**). Participants were asked to perform the somatomotor task, while a pseudo-randomized delay of 0, 250 or 500 ms was introduced between the hand movement and the tactile feedback on the back. On each trial, each patient performed 10 successive poking movements (automatically counted) and immediately afterwards gave a "Yes" or "No" answer to the following question assessing riPH: "Did you feel as if someone was standing close by — behind or next to you?". Each patient underwent 12 trials per delay (total of 36 trials). Breaks between sessions allowed patients to avoid physical discomfort and fatigue.

FIG. 1. Robotic somatomotor stimulation task. Participant using the robotic system with a front robot and a back robot. A robot-induced PH (riPH) is schematically shown behind the participant.

Statistical analysis

All statistical analyses were conducted using R (version 4.5.0) within RStudio (version 2025.05.0). To compare the PD-MH and PD-nH groups in terms of socio-demographic characteristics, clinical features, and scores from the neuropsychological tests, independent Welch's t-test were performed. For the robotic somatomotor stimulation task, data from 23 PD-MH and 25 PD-nH patients was analyzed, as 2 patients from the PD-MH group did not complete the task due to severe dyskinesia. The "yes" responses to the riPH question were averaged for each subject and "delay" (0, 250, 500 ms). A first linear regression model was used to analyze patients' sensitivity to riPH, with the mean of "Yes" responses as the dependent variable and "group" (PD-MH and PD-nH) as a categorial predictor and "delay" (0, 250, 500 ms) as a continuous predictor. To examine the relationship between neuropsychological performance and sensitivity to riPH, we conducted a series of linear regression analyses. In each model, the dependent variable was the mean of "Yes" responses

to riPH, averaged across the three delay conditions, to index the global riPH sensitivity for each subject. Group (PD-MH vs. PD-nH) was included as a categorical factor and scores from each neuropsychological test served as continuous predictors. These included the frontal-subcortical, posterior cortical, and total scores from the PD-CRS; the number of self-corrected and non-corrected errors on the TMT parts A and B; and the number of self-corrected and non-corrected errors on the Stroop test (conditions 3 and 4). Interaction terms between group and each cognitive variable were included to test whether the relationship between cognitive performance and riPH sensitivity differed by group.

To ensure that the observed relationships between riPH global sensitivity and cognitive performance were not confounded by clinical or demographic variables, additional linear regression models were run including covariates of no interest: age, education, disease duration, LEDD, MDS-UPDRS scores (parts I–IV), Hoehn & Yahr stage, and depression and anxiety scores. These adjusted models tested whether the interaction between group (PD-MH vs. PD-nH) and cognitive variables remained significant after accounting for these covariates, confirming that the association between cognitive impairment and riPH sensitivity differs by group and is not explained by other clinical or demographic factors.

Bonferroni correction was applied for eleven planned comparisons involving the following predictors: PD-CRS frontal subcortical, PD-CRS posterior cortical and total PD-CRS scores; self-corrected and non-corrected errors of Stroop test (conditions 3 and 4), and self-corrected and non-corrected errors of TMT parts A and B, each interacting with subgroup. Statistical significance was set at $P<0.05$.

TABLE 1. *Socio-demographic and clinical characteristics of patients.*

	PD-MH (n=25)		PD-nH (n=25)		Welch's t-test		
	M	SD	M	SD	t	df	*P*
Age (years)	68.09	8.11	66.12	8.92	0.65	47.32	0.52
Sex	1.65	0.49	1.72	0.46	-0.3	47.93	0.76
Education (years)	10.70	4.16	9.12	4.53	0.92	41.24	0.36
Illness duration (years)	16.59	4.94	15.28	3.14	1.19	47.31	0.24
Total LEDD (mg)	879.78	445.21	751.89	468.82	0.99	47.58	0.32
MDS-UPDRS I	14.74	7.24	7.32	4.85	3.78	41.40	<0.001***
MDS-UPDRS II	13.78	7.22	9.36	5.84	2.23	46.41	0.03*
MDS-UPDRS III	21.22	9.86	19.56	12.38	0.31	45.47	0.76
MDS-UPDRS IV	4.35	3.66	2.08	3.35	2.29	47.28	0.03*
Hoehn & Yahr stage	2.04	0.71	1.90	0.56	0.78	41.93	0.44
Anxiety (HADS)	7.09	2.97	5.12	2.64	2.16	47.29	0.04*
Depression (HADS)	6.13	3.96	4.24	2.98	1.67	44.88	0.10

*$P<0.05$.
**$P<0.01$.
***$P<0.001$.

Abbreviations: LEDD, levodopa equivalent daily dosage; MDS-UPDRS, Movement Disorder Society-Unified Parkinson's Disease Rating Scale; HADS, Hospital Anxiety and Depression Scale.

Results

Clinical evaluation

In the PD-MH group, passage hallucinations were the most common (68%), followed by presence hallucinations (60%) and visual illusions/misperceptions (56%). The different types of MH and their co-occurrence among the PD-MH group are illustrated in the Supplementary Information 2 (**FIG. S1**).

There was no significant difference between the PD-MH and PD-nH groups in terms of age, sex, education, illness duration, LEDD and depression scores (all Ps>0.05). Non-motor symptoms (MDS-UPDRS I; t=3.78; df=41.40; P<0.001), activities of daily living (MDS-UPDRS II; t=2.23; df=46.41; P=0.03), and motor complications (MDS-UPDRS IV, t=2.29; df=47.28; P=0.03) were rated as mildly but significantly more severe by the PD-MH group than the PD-nH group. However, the severity of motor symptoms (MDS-UPDRS III) was not significantly different between the two groups (t=0.31; df=45.47; P=0.76). Hoehn and Yahr staging of severity of PD also did not differ significantly between both groups (t=0.78; df=41.93; P=0.44). Additionally, PD-MH patients had significantly higher anxiety levels than the PD-nH group (t=2.16; df=47.29; P=0.04) while no significant difference was observed for depression as measured by the HADS (TABLE 1).

Neuropsychological evaluation

Analyses of behavioral performance on neuropsychological tests assessing general cognition (MoCA), frontal subcortical and posterior cortical functions (PD-CRS), as well as cognitive flexibility, resistance to interference and inhibitory control (number of errors in TMT-A and B and in the Stroop color-word test) did not reveal any significant group differences between PD-MH and PD-nH patients (all Ps>0.05). The total scores on the MoCA and PD-CRS indicated preserved cognitive functioning, falling above the established thresholds for both dementia and

mild cognitive impairment (see TABLE 2). However, PD-MH patients reported significantly higher subjective cognitive decline or complaints in daily life compared to PD-nH patients (t=4.85; df=34.00; P<0.001). A detailed summary of the neuropsychological results for both groups is presented in TABLE 2.

TABLE 2. *Neuropsychological score differences between PD patient groups.*

	PD-MH (n=25)		PD-nH (n=25)		Welch's t-test		
	M	SD	M	SD	t	df	*P*
MoCA	27.26	2.23	26.35	3.08	0.5	46.98	0.61
PD-CRS							
PD-CRS total total score	99.16	13.26	99.04	14.79	-1.31	47.19	0.19
PD-CRS frontal subcortical score	70.11	13.38	70.22	13.58	-1.34	46.71	0.19
PD-CRS posteror cortical score	29.05	1.03	28.83	2.08	-0.44	47.6	0.66
TMT part A							
Non-corrected errros	0.05	0.23	0.04	0.21	0.62	41.31	0.54
Self-corrected errors	0.11	0.32	0.04	0.21	0.62	41.31	0.54
TMT part B							
Non-corrected errors	0.84	0.96	0.96	1.58	-0.11	43.71	0.91
Self-corrected errors	0.42	0.69	0.39	0.58	0.41	41.88	0.68
Stroop Resistance to interference (condition 3)							
Non-corrected errors	0.63	1.83	0.52	2.09	0.83	36.29	0.41
Self-corrected errors	1.47	1.9	1.26	1.14	1.02	28.86	0.32
Resistance to interference/cognitive flexibility (condition 4)							
Non-corrected errors	1.58	2.09	1.96	2.77	-0.5	39.71	0.62
Self-corrected errors	1.21	1.69	1.00	1.17	0.46	31.01	0.65
Subjective cognitive decline							
MDS-UPDRS 1-1	1.26	1.15	0.3	0.56	4.85	34	<0.001***

*P<0.05.

**P<0.01.

***P<0.001.

Abbreviations: MoCA, Montreal Cognitive Assessment; PD-CRS, Parkinson's Disease-Cognitive Rating Scale; TMT, Trail Making Test.

Robot-induced presence hallucinations (riPH)

We found that the PD-MH group had a significantly higher riPH sensitivity (indexed by a higher proportion of affirmative responses in the PH-inducing robotic procedure) than the PD-nH group, as indicated by a main effect of group ($\beta=0.039$, SE=0.012, t=3.39, $P<0.001$) (**FIG. 2**). A main effect of delay was also found ($\beta=0.00022$, SE=0.000036, t= 4.77, $P<0.001$). Consistent with previous findings (36), this result indicates that PD-MH patients showed higher sensitivity to conflicting somatomotor stimulation than PD-nH patients. The interaction between group and delay was not significant ($\beta=0.000035$, SE=0.000036, t=0.98, $P=0.33$). The model explained a significant portion of variance ($R^2=0.047$, F(3, 1631)=27.02, $P<0.001$).

FIG. 2. Sensitivity to somatomotor conflicts. Higher proneness to riPH and higher delay sensitivity in PD-MH (purple) vs. PD-nPH (orange). Thick line: mean of fitted model; shaded area: 95% confidence interval. **$P<0.01$.

Relationship between riPH and neuropsychology

PD-CRS

We first examined the relationship between group, riPH sensitivity, and neuropsychological scores (using the PD-CRS evaluations) and found that riPH sensitivity is differently modulated

by group and frontal subcortical score (i.e., a significant interaction between the two terms) (β=-0.00141, SE=0.00045, t=-3.16, *P*=0.001). Specifically, the significant interaction showed a difference in riPH sensitivity between the two groups at the lowest frontal subcortical scores (i.e., more impaired frontal subcortical functions) (**FIG. 3A**) with higher sensitivity more pronounced in PD-MH (**FIG. 3A**, purple line) compared to PD-nH patients (**FIG. 3A**, orange line). This interaction was absent between group and the posterior scores of the PD-CRS on riPH sensitivity (*P*>0.05) (**FIG. 3B**). For all remaining effects, see Supplementary Information 3.

FIG. 3. Correlations between PD-CRS and robot-induced presence hallucinations (riPH) differ between PD-MH and PD-nH. A. The relationship between frontal subcortical scores and mean "Yes" responses indicates that lower scores, i.e., impaired frontal subcortical functions, are associated with higher proneness to riPH, with PD-MH patients (purple) showing greater sensitivity to riPH than PD-nH ones (orange). **B.** This relationship is not significant for posterior cortical scores. Shaded areas represent the 95% confidence intervals around the regression lines. *******P*<0.01. n.s >0.05.

Stroop color-word test

Second, we examined how riPH sensitivity relates to performance on the Stroop test. Specifically, in condition 4 of the Stroop test, riPH sensitivity was differentially associated with error rates depending on group, as shown by a significant interaction between group and both

the number of self-corrected errors (β=0.038, SE=0.007, t=5.85, *P*<0.001; **FIG. 4A**), and non-corrected errors (β=0.001, SE=0.003, t=2.88, *P*=0.004; **FIG. 4B**). These results indicate that the relationship between errors in the Stroop test and riPH sensitivity was stronger in PD-MH than in PD-nH patients. Precisely, in the PD-MH group (but not the PD-nH group), a higher number of errors (both self-corrected and non-corrected) was associated with greater riPH sensitivity. This finding extends the result observed with the frontal subcortical PD-CRS score and provides novel evidence that impaired resistance to interference and cognitive flexibility are linked to elevated riPH sensitivity in the PD-MH, but not the PD-nH group (*P*<0.01) (**FIG. 4A and 4B**). See Supplemental Information 3 for all remaining effects and results, including TMT.

The relationship between cognitive performance (frontal subcortical scores and Stroop error rates) and sensitivity to riPH remained significant after controlling for key clinical and demographic variables (covariate of non-interest) such as age, disease duration, LEDD, motor and non-motor symptoms severity, stage of illness, and mood symptoms (anxiety and depression) (all *Ps*<.0.001).

FIG. 4. Correlations between resistance to interference, cognitive flexibility and robot-induced hallucinations (riPH). A and B. As the number of self-corrected and non-corrected errors increases in the Stroop test (condition 4), PD-MH patients (purple line) show a significantly greater sensitivity to riPH compared to PD-nH patients (orange line). Shaded areas represent the 95% confidence intervals around the regression lines. ***P*<0.001, ***P*<0.01.

Discussion

The main objective of this study was to determine whether MH, one of the most frequent and early-occurring hallucinations in PD, are associated with cognitive deficits and how this potential relationship depends on sensitivity to the riPH procedure. For this, we combined in depth neurological and neuropsychological examinations with an experimental approach during which PH are induced in patients by means of a robotic device delivering conflicting somatomotor stimulations (36,39,40). This extends earlier studies, which analyzed the relationship between hallucinations and neuropsychology by classifying PD patients only based on interviews or self-reports about having or not hallucinations. By providing an additional real-time measure of PH susceptibility, this approach may allow for the detection of more subtle cognitive vulnerabilities linked to MH. Consistent with our hypothesis, we report (1) a significant association between increased sensitivity to riPH and frontal subcortical deficits and especially to impairments in resistance to interference, inhibitory control, and cognitive flexibility. Critically, this relationship was particularly (2) strong in the PD-MH group and differed from PD-nH patients. In contrast, (3) no significant association was found between riPH sensitivity and posterior cortical functions, and (4) did not relate to clinical and demographic differences between groups. These findings provide robust evidence that MH are associated with frontal subcortical impairments in PD (37,44) and we argue that the present approach - the combination of the riPH procedure with neurological and neuropsychological examinations - allows the quantification of a more subtle relationship between MH and frontal (executive) dysfunction that standard clinical assessments may fail to capture.

Cognitive impairments involving frontal subcortical circuits are well documented in PD, independent of hallucination status of patients (17,53–55). While both frontal subcortical and posterior cortical dysfunctions have been consistently associated with structured visual hallucinations (13,25,56), the cognitive correlates of MH remained elusive. It has been argued that this is likely due to the lack of sensitive assessment methods capable of detecting more subtle frontal subcortical deficits in PD patients with MH. Accordingly, PD-MH versus PD-nH

groups often show only small and non-significant differences on standard neuropsychological tests (8,38,57). In the present study, we also found comparable neuropsychological performance between PD-MH and PD-nH groups on frontal subtests (7,8,35), but we report two novel findings, allowing to discriminate between both groups' frontal subcortical functions. First, we report that riPH sensitivity, in both groups, was significantly associated with lower frontal subscale scores, linking more impaired frontal subcortical functions with higher sensitivity to robotic somatomotor stimulation. Second, this relationship was more pronounced in those PD-MH patients who had more impaired frontal subcortical scores, differing significantly from PD-nH patients (**FIG.3A**). These findings extend prior research implicating frontal lobe dysfunction in MH, but only if the additional measure of sensitivity to riPH was included (7,34–36,58). The riPH measure is based on exposure to conflicting somatomotor signals (tactile, proprioceptive, motor) and has been shown to recruit a frontal subcortical network consisting of primary somatomotor cortex, premotor cortex, supplementary motor cortex and basal ganglia ((36), Fig.S5). Combining riPH sensitivity with standard frontal subcortical tests as included in the PD-CRS, we distinguished PD-MH from PD-nH by revealing a neuropsychological deficit that linked higher riPH sensitivity with lower frontal subcortical functions, in PH-MH.

These data were corroborated by additional testing with the Stroop test assessing inhibitory control, cognitive flexibility, and resistance to interference functions mediated by prefrontal networks (38,59,60). Thus, as for the PD-CRS findings, initial group comparisons, based on neuropsychological results on error rates, revealed no significant differences between PD-MH and PD-nH patients in the present study. However, combining riPH sensitivity with Stroop errors revealed that increased riPH sensitivity was associated with poorer performance, with higher number of errors in PH-MH versus PD-nH. Recent studies (38,61) using the Stroop test hypothesized that performance on this test would be significantly associated with the occurrence of hallucinations in PD patients, but did not show any significant difference between PD-MH and PD-nH patients.

Taken together, these findings show that the combination of riPH sensitivity with frontal neuropsychology allows to describe a subtle 'minor' frontal lobe deficit in PD-MH patients that was absent for posterior brain functions. Thus, riPH sensitivity was not associated with cognitive domains related to posterior cortical functioning, neither in the PD-MH nor the PD-nH group. We argue accordingly that posterior functions and related brain regions, which are typically altered in PD patients with structured visual hallucinations and associated with later cognitive decline or dementia (19,27,30), are still preserved at the MH stage of PD. These findings support the idea that MH stem from frontal subcortical dysfunction, rather than more widespread cortical impairment, involving posterior brain regions (7,30,44). Although we found that PD-MH patients had higher anxiety levels and slightly higher sub-scores in motor and non-motor experiences of daily living (MDS-UPDRS I, II), and motor complications (MDS-UPDRS IV), we also note that the present findings cannot be explained by clinical variables like motor symptom severity (MDS-UPDRS III), disease duration and stage of PD, level of medication (LEDD) and mood disturbances that have been associated previously with hallucinations and/or cognitive deficits (1,2,55,57,62–64). Furthermore, the relationship between frontal subcortical impairments and riPH sensitivity was not attributable to sociodemographic factors such as age, sex or level of education. Overall, the present findings, support the hypothesis that MH could serve as an independent predictor of cognitive impairment in PD (38,45,65), but only if combined with riPH measurements, as PD-MH with low riPH sensitivity had more preserved frontal subcortical functions and did not differ from PD-nH. Finally, we note that PD-MH patients also reported significantly greater subjective cognitive complaints compared to PD-nH patients. Subjective cognitive decline, especially if combined with neuropsychological testing and riPH measurements, should receive greater attention in clinical settings (24,35,66), as they may also indicate early cognitive changes that remain undetected by standard neuropsychological testing in patients with normal or near-normal performance. Overall, the present data suggest that patients with MH should be followed up carefully and if available tested with riPH measures or related somatomotor procedures to better identify and manage cognitive impairments and their appearance (67–69).

The present study has several limitations. First, our study being cross-sectional, it does not allow to capture the progression of the frontal subcortical (and other) impairments of PD-MH over time. Second, since PD-nH patients did not experience hallucinations at the time of the study, it is possible that part of the patients would develop them later, as observed in previous longitudinal studies (70–72). In line with this, we found that several PD-nH patients already showed higher riPH sensitivity associated with poorer performance on frontal subcortical functions. These PD-nH patients might reflect an early vulnerability (35,38) and could be at higher risk of developing MH (and later structured visual hallucinations), suggesting the need for closer follow-up in future studies. Finally, we assessed subjective cognitive complaints with a single question from the MDS-UPDRS scale, but upcoming studies would benefit from using a more comprehensive questionnaire to evaluate subjective cognitive decline, and look for potential interference with psychiatric comorbidities such as anxiety.

In conclusion, our study demonstrates that PD-MH versus PD-nH is associated with frontal subcortical executive impairments that depend on riPH sensitivity. Future brain imaging and electrophysiological research should investigate the neural mechanisms underlying this association and longitudinal studies will be important to describe the clinical and neuropsychological trajectory of PD-MH patients over time.

Acknowledgement

The authors would like to express their sincere gratitude to all the patients for their valuable time, effort, and for sharing their personal experiences with hallucinations. We also extend our thanks to Dr. Atena Fadaei Jouybari for her contribution to the design of **FIG. 1**.

Study data were collected and managed using REDCap electronic data capture tools hosted at the Swiss Federal School of Technology (Ecole Polytechnique Fédérale de Lasaunne). REDCap (Research Electronic Data Capture) is a secure, web-based software platform designed to support data capture for research studies, providing 1) an intuitive interface for validated data capture; 2) audit trails for tracking data manipulation and export procedures; 3) automated export procedures for seamless data downloads to common statistical packages; and 4) procedures for data integration and interoperability with external sources.

Authors' roles

(1) Research project: A. Conception, B. Organization, C. Execution; (2) Statistical Analysis: A. Design, B. Execution, C. Review and Critique; (3) Manuscript Preparation: A. Writing of the first draft, B. Review and Critique.

J.P.: 1A, 1B, 1C, 2A, 2B, 2C, 3A, 3B

L.F.D.P.T: 1B, 1C, 3B

M.E.M-G.: 1B, 1C, 3B

C.S.: 1B, 1C, 3B

N.H.M.: 2C, 3B

F.B.: 2A, 2C, 3B

L.J.: 1A, 3B

J.F.B.: 1B, 3B

M.C.J: 1B

V.F-N.: 1B, 3B

J.H.: 1B, 3B

B.W.: 1B, 3B

J.P.M.: 1B, 3B

P.K.: 1B, 3B

O.B.: 1A, 1B, 2C, 3B

Ethical compliance statement

The study was approved by the cantonal ethics committees of Geneva, Vaud and Bern (Switzerland) under protocol number 2019-02275. All participants were presented to the study orally and by means of a written information sheet. All participants gave their written informed consent prior enrollment in the study. We confirm that we have read the Journal's position on issues involved in ethical publication and affirm that this work is consistent with those guidelines.

Financial disclosures of all authors (for the preceding 12 months)

The authors declare that there are no additional disclosures to report. OB is one of the inventors on patent US 10,286,555 B2 (Title: Robot-controlled induction of the feeling of a presence) held by the Swiss Federal Institute (EPFL) that covers the robot-induction of the presence hallucinations (riPH). O.B. is one of the inventors on patent US 10,349,899 B2 (Title: System and method for predicting hallucinations) held by the Swiss Federal Institute (EPFL) that covers a robotic system for the prediction of hallucinations for diagnostic purposes.

References

1.	Fénelon G, Mahieux F, Huon R, Ziégler M. Hallucinations in Parkinson's disease: prevalence, phenomenology and risk factors. Brain. 2000 Apr;123 (Pt 4):733–45.

2.	Ffytche DH, Pereira JB, Ballard C, Chaudhuri KR, Weintraub D, Aarsland D. Risk factors for early psychosis in PD: insights from the Parkinson's Progression Markers Initiative. J Neurol Neurosurg Psychiatr. 2017 Apr;88(4):325–31.

3.	Mack J, Rabins P, Anderson K, Goldstein S, Grill S, Hirsch ES, et al. Prevalence of psychotic symptoms in a community-based Parkinson disease sample. Am J Geriatr Psychiatry. 2012 Feb;20(2):123–32.

4.	Ffytche DH, Creese B, Politis M, Chaudhuri KR, Weintraub D, Ballard C, et al. The psychosis spectrum in Parkinson disease. Nat Rev Neurol. 2017 Feb;13(2):81–95.

5.	Weintraub D, Aarsland D, Chaudhuri KR, Dobkin RD, Leentjens AF, Rodriguez-Violante M, et al. The neuropsychiatry of Parkinson's disease: advances and challenges. The Lancet Neurology. 2022 Jan 1;21(1):89–102.

6.	Albert L, Vehar N, Potheegadoo J, Bernasconi F, Blanke O. Visual hallucinations in Parkinson's disease are associated with deficits in social perception. Journal of Parkinson's Disease. 2025 May 4;1877718X251336196.

7.	Pagonabarraga J, Bejr-Kasem H, Martinez-Horta S, Kulisevsky J. Parkinson disease psychosis: from phenomenology to neurobiological mechanisms. Nat Rev Neurol. 2024 Jan 15;1–16.

8.	Llebaria G, Pagonabarraga J, Martínez-Corral M, García-Sánchez C, Pascual-Sedano B, Gironell A, et al. Neuropsychological correlates of mild to severe hallucinations in Parkinson's disease. Mov Disord. 2010 Dec 15;25(16):2785–91.

9.	Diederich NJ, Fénelon G, Stebbins G, Goetz CG. Hallucinations in Parkinson disease. Nat Rev Neurol. 2009 Jun;5(6):331–42.

10.   Aarsland D, Larsen JP, Tandberg E, Laake K. Predictors of nursing home placement in Parkinson's disease: a population-based, prospective study. J Am Geriatr Soc. 2000 Aug;48(8):938–42.

11.   Goetz CG, Stebbins GT. Risk factors for nursing home placement in advanced Parkinson's disease. Neurology. 1993 Nov;43(11):2227–9.

12.   Fénelon G, Soulas T, Zenasni F, De Langavant LC. The changing face of Parkinson's disease-associated psychosis: a cross-sectional study based on the new NINDS-NIMH criteria. Mov Disord. 2010 Apr;25(6):755–9.

13.   Santangelo G, Trojano L, Vitale C, Ianniciello M, Amboni M, Grossi D, et al. A neuropsychological longitudinal study in Parkinson's patients with and without hallucinations. Movement Disorders. 2007;22(16):2418–25.

14.   Pisani S, Gosse L, Aarsland D, Ray Chaudhuri K, Ballard C, Ffytche D, et al. Parkinson's disease psychosis associated with accelerated multidomain cognitive decline. BMJ Ment Health. 2024 Jul 23;27(1):1–10.

15.   Factor SA, Scullin MK, Sollinger AB, Land JO, Wood-Siverio C, Zanders L, et al. Cognitive correlates of hallucinations and delusions in Parkinson's disease. J Neurol Sci. 2014 Dec 15;347(1–2):316–21.

16.   Emre M, Aarsland D, Brown R, Burn DJ, Duyckaerts C, Mizuno Y, et al. Clinical diagnostic criteria for dementia associated with Parkinson's disease. Mov Disord. 2007 Sep 15;22(12):1689–707; quiz 1837.

17.   Litvan I, Goldman JG, Tröster AI, Schmand BA, Weintraub D, Petersen RC, et al. Diagnostic criteria for mild cognitive impairment in Parkinson's disease: Movement Disorder Society Task Force guidelines. Mov Disord. 2012 Mar;27(3):349–56.

18.   Poewe W, Gauthier S, Aarsland D, Leverenz JB, Barone P, Weintraub D, et al. Diagnosis and management of Parkinson's disease dementia. Int J Clin Pract. 2008 Oct;62(10):1581–7.

19.   Devignes Q, Viard R, Betrouni N, Carey G, Kuchcinski G, Defebvre L, et al. Posterior Cortical Cognitive Deficits Are Associated With Structural Brain Alterations in Mild Cognitive Impairment in Parkinson's Disease. Frontiers in Aging Neuroscience [Internet]. 2021 [cited 2022 Feb 20];13. Available from:

https://www.frontiersin.org/article/10.3389/fnagi.2021.668559

20.   Chandler JM, Nair R, Biglan K, Ferries EA, Munsie LM, Changamire T, et al. Characteristics of Parkinson's Disease in Patients with and without Cognitive Impairment. Journal of Parkinson's Disease. 2021 Jan 1;11(3):1381–92.

21.   Weil RS, Costantini AA, Schrag AE. Mild Cognitive Impairment in Parkinson's Disease—What Is It? Curr Neurol Neurosci Rep. 2018;18(4):17.

22.   Biundo R, Bezdicek O, Cammisuli DM, Cholerton B, Dalrymple-Alford JC, Edelstyn N, et al. Attention/Working Memory and Executive Function in Parkinson's Disease: Review, Critique, and Recommendations. Movement Disorders [Internet]. 2025 [cited 2025 Jul 30];n/a(n/a). Available from: https://onlinelibrary.wiley.com/doi/abs/10.1002/mds.30293

23.   Williams DR, Warren JD, Lees AJ. Using the presence of visual hallucinations to differentiate Parkinson's disease from atypical parkinsonism. J Neurol Neurosurg Psychiatry. 2008 Jun;79(6):652–5.

24.   Santos-García D, de Deus Fonticoba T, Cores Bartolomé C, Feal Painceiras MJ, Paz González JM, Martínez Miró C, et al. Risk of Cognitive Impairment in Patients With Parkinson's Disease With Visual Hallucinations and Subjective Cognitive Complaints. J Clin Neurol. 2023 Jan 2;

25.   Pezzoli S, Sánchez-Valle R, Solanes A, Kempton MJ, Bandmann O, Shin JI, et al. Neuroanatomical and cognitive correlates of visual hallucinations in Parkinson's disease and

dementia with Lewy bodies: Voxel-based morphometry and neuropsychological meta-analysis. Neurosci Biobehav Rev. 2021 Sep;128:367–82.

26.   Kehagia AA, Barker RA, Robbins TW. Neuropsychological and clinical heterogeneity of cognitive impairment and dementia in patients with Parkinson's disease. Lancet Neurol. 2010 Dec;9(12):1200–13.

27.   Puig-Davi A, Martinez-Horta S, Pérez-Carasol L, Horta-Barba A, Ruiz-Barrio I, Aracil-Bolaños I, et al. Prediction of Cognitive Heterogeneity in Parkinson's Disease: A 4-Year Longitudinal Study Using Clinical, Neuroimaging, Biological and Electrophysiological Biomarkers. Annals of Neurology [Internet]. 2024 Aug 5 [cited 2024 Aug 12];n/a(n/a). Available from: https://onlinelibrary.wiley.com/doi/full/10.1002/ana.27035

28.   Barnes J, Boubert L. Executive functions are impaired in patients with Parkinson's disease with visual hallucinations. J Neurol Neurosurg Psychiatry. 2008 Feb;79(2):190–2.

29.   Creese B, Albertyn CP, Dworkin S, Thomas RS, Wan YM, Ballard C. Executive function but not episodic memory decline associated with visual hallucinations in Parkinson's disease. J Neuropsychol. 2018 Jul 23;

30.   Pagonabarraga J, Kulisevsky J, Llebaria G, García-Sánchez C, Pascual-Sedano B, Gironell A. Parkinson's disease-cognitive rating scale: a new cognitive scale specific for Parkinson's disease. Mov Disord. 2008 May 15;23(7):998–1005.

31.   Ozer F, Meral H, Hanoglu L, Ozturk O, Aydemir T, Cetin S, et al. Cognitive impairment patterns in Parkinson's disease with visual hallucinations. Journal of Clinical Neuroscience. 2007 Aug 1;14(8):742–6.

32.   Grossi D, Trojano L, Pellecchia MT, Amboni M, Fragassi NA, Barone P. Frontal dysfunction contributes to the genesis of hallucinations in non-demented Parkinsonian patients. International Journal of Geriatric Psychiatry. 2005;20(7):668–73.

33.   Pagonabarraga J, Martinez-Horta S, Fernández de Bobadilla R, Pérez J, Ribosa-Nogué R, Marín J, et al. Minor hallucinations occur in drug-naive Parkinson's disease patients, even from the premotor phase. Mov Disord. 2016 Jan;31(1):45–52.

34.   Bejr-kasem H, Pagonabarraga J, Martínez-Horta S, Sampedro F, Marín-Lahoz J, Horta-Barba A, et al. Disruption of the default mode network and its intrinsic functional connectivity underlies minor hallucinations in Parkinson's disease. Movement Disorders. 2019;34(1):78–86.

35.   Bejr-Kasem H, Sampedro F, Marín-Lahoz J, Martínez-Horta S, Pagonabarraga J, Kulisevsky J. Minor hallucinations reflect early gray matter loss and predict subjective cognitive decline in Parkinson's disease. Eur J Neurol. 2021 Feb;28(2):438–47.

36.   Bernasconi F, Blondiaux E, Potheegadoo J, Stripeikyte G, Pagonabarraga J, Bejr-Kasem H, et al. Robot-induced hallucinations in Parkinson's disease depend on altered sensorimotor processing in fronto-temporal network. Sci Transl Med. 2021 Apr 28;13(591):eabc8362.

37.   Bejr-kasem H, Martínez-Horta S, Pagonabarraga J, Marín-Lahoz J, Horta-Barba A, Sampedro F, et al. The role of attentional control over interference in minor hallucinations in Parkinson's disease. Parkinsonism & Related Disorders. 2022 Sep 1;102:101–7.

38.   Lenka A, Hegde S, Arumugham SS, Singh P, Yadav R, Pal PK. Cognitive Correlates of Visual and Minor Hallucinations in Parkinson's Disease. Canadian Journal of Neurological Sciences. 2023 Jan;50(1):44–8.

39.   Bernasconi F, Blondiaux E, Rognini G, Dhanis H, Jenni L, Potheegadoo J, et al. Neuroscience robotics for controlled induction and real-time assessment of hallucinations. Nat Protoc. 2022 Sep 12;1–24.

40.   Blanke O, Pozeg P, Hara M, Heydrich L, Serino A, Yamamoto A, et al. Neurological and robot-controlled induction of an apparition. Curr Biol. 2014 Nov 17;24(22):2681–6.

41.	Albert L, Potheegadoo J, Herbelin B, Bernasconi F, Blanke O. Numerosity estimation of virtual humans as a digital-robotic marker for hallucinations in Parkinson's disease. Nat Commun. 2024 Mar 12;15(1):1905.

42.	Potheegadoo J, Dhanis H, Horvath J, Burkhard PR, Blanke O. Presence Hallucinations during Locomotion in Patients with Parkinson's Disease. Mov Disord Clin Pract. 2022 Jan;9(1):127–9.

43.	Salomon R, Progin P, Griffa A, Rognini G, Do KQ, Conus P, et al. Sensorimotor Induction of Auditory Misattribution in Early Psychosis. Schizophrenia Bulletin. 2020 Feb 11;sbz136.

44.	Bernasconi F, Pagonabarraga J, Bejr-Kasem H, Martinez-Horta S, Marín-Lahoz J, Horta-Barba A, et al. Theta oscillations and minor hallucinations in Parkinson's disease reveal decrease in frontal lobe functions and later cognitive decline. Nat Mental Health. 2023 Jul;1(7):477–88.

45.	Lenka A, George L, Arumugham SS, Hegde S, Reddy V, Kamble N, et al. Predictors of onset of psychosis in patients with Parkinson's disease: Who gets it early? Parkinsonism & Related Disorders. 2017 Nov 1;44:91–4.

46.	Hughes AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry. 1992 Mar 1;55(3):181–4.

47.	Goetz CG, Tilley BC, Shaftman SR, Stebbins GT, Fahn S, Martinez-Martin P, et al. Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): scale presentation and clinimetric testing results. Mov Disord. 2008 Nov 15;23(15):2129–70.

48.	Zigmond AS, Snaith RP. The hospital anxiety and depression scale. Acta Psychiatr Scand. 1983 Jun;67(6):361–70.

49.   Nasreddine ZS, Patel BB. Validation of Montreal Cognitive Assessment, MoCA, Alternate French Versions. Can J Neurol Sci. 2016 Sep;43(5):665–71.

50.   Reitan RM, Wolfson D. The Halstead-Reitan Neuropsychological Test Battery: Theory and Clinical Interpretation. Neuropsychology Press; 1985. 512 p.

51.   Stroop JR. Studies of interference in serial verbal reactions. J Exp Psychol. 1935;643–62.

52.   Blanke O, Bernasconi F, Potheegadoo J. Phantom Boarder Relates to Experimentally-Induced Presence Hallucinations in Parkinson's Disease. Mov Disord Clin Pract. 2023 Apr;10(4):617–24.

53.   Kulisevsky J, Pagonabarraga J. Cognitive impairment in Parkinson's disease: tools for diagnosis and assessment. Mov Disord. 2009 Jun 15;24(8):1103–10.

54.   Gul A, Yousaf J, Ahmad H. Frontal-subcortical defects correlate with task switching deficits in Parkinson's disease. Neurosciences (Riyadh). 2017 Jul;22(3):224–7.

55.   Aarsland D, Batzu L, Halliday GM, Geurtsen GJ, Ballard C, Ray Chaudhuri K, et al. Parkinson disease-associated cognitive impairment. Nat Rev Dis Primers. 2021 Jul 1;7(1):1–21.

56.   Gryc W, Roberts KA, Zabetian CP, Weintraub D, Trojanowski JQ, Quinn JF, et al. Hallucinations and Development of Dementia in Parkinson's Disease. J Parkinsons Dis. 2020;10(4):1643–8.

57.   Flanigan JL, Harrison MB, Patrie JT, Shah BB, Sperling SA, Wyman-Chick KA, et al. Clinical and cognitive features associated with psychosis in Parkinson's disease: a longitudinal study. Front Aging Neurosci. 2024 Nov 6;16:1463426.

58.   Ozawa M, Shiraishi T, Murakami H, Yoshimaru D, Onda A, Matsuno H, et al. Structural MRI study of Pareidolia and Visual Hallucinations in Drug-Naïve Parkinson's disease. Sci Rep. 2024 Dec 28;14(1):31293.

59.   Stam CJ, Visser SL, Op de Coul AA, De Sonneville LM, Schellens RL, Brunia CH, et al. Disturbed frontal regulation of attention in Parkinson's disease. Brain. 1993 Oct;116 (Pt 5):1139–58.

60.   Costa A, Peppe A, Mazzù I, Longarzo M, Caltagirone C, Carlesimo GA. Dopamine Treatment and Cognitive Functioning in Individuals with Parkinson's Disease: The "Cognitive Flexibility" Hypothesis Seems to Work. Behavioural Neurology. 2014 Jan 30;2014:e260896.

61.   Pisani S, Gosse L, Wieretilo R, Ffytche D, Velayudhan L, Bhattacharyya S. Cognitive and executive impairments in Parkinson's disease psychosis: a Bayesian meta-analysis. J Neurol Neurosurg Psychiatry [Internet]. 2023 Jul 19 [cited 2023 Aug 2]; Available from: https://jnnp.bmj.com/content/early/2023/07/19/jnnp-2022-331028

62.   Fénelon G, Alves G. Epidemiology of psychosis in Parkinson's disease. J Neurol Sci. 2010 Feb 15;289(1–2):12–7.

63.   Omoto S, Murakami H, Shiraishi T, Bono K, Umehara T, Iguchi Y. Risk factors for minor hallucinations in Parkinson's disease. Acta Neurol Scand. 2021 May;143(5):538–44.

64.   Zhong M, Gu R, Zhu S, Bai Y, Wu Z, Jiang X, et al. Prevalence and Risk Factors for Minor Hallucinations in Patients with Parkinson's Disease. Behav Neurol. 2021 Oct 4;2021:3469706.

65.   Schneider RB, Mills KA, Nirenberg MJ, Dobkin RD, Pontone GM. Defining the Importance of Minor Hallucinations in Parkinson's Disease. Movement Disorders. 2024;39(6):1083–1083.

66.   Dujardin K, Duhamel A, Delliaux M, Thomas-Antérion C, Destée A, Defebvre L. Cognitive complaints in Parkinson's disease: its relationship with objective cognitive decline. J Neurol. 2010 Jan;257(1):79–84.

67.   Pozeg P, Rognini G, Salomon R, Blanke O. Crossing the hands increases illusory self-touch. PLoS ONE. 2014;9(4):e94008.

68.   Weiskrantz L, Elliott J, Darlington C. Preliminary observations on tickling oneself. Nature. 1971 Apr 30;230(5296):598–9.

69.   Blakemore SJ, Smith J, Steel R, Johnstone CE, Frith CD. The perception of self-produced sensory stimuli in patients with auditory hallucinations and passivity experiences: evidence for a breakdown in self-monitoring. Psychol Med. 2000 Sep;30(5):1131–9.

70.   Forsaa EB, Larsen JP, Wentzel-Larsen T, Goetz CG, Stebbins GT, Aarsland D, et al. A 12-Year Population-Based Study of Psychosis in Parkinson Disease. Archives of Neurology. 2010 Aug 1;67(8):996–1001.

71.   Goetz CG, Leurgans S, Pappert EJ, Raman R, Stemer AB. Prospective longitudinal assessment of hallucinations in Parkinson's disease. Neurology. 2001 Dec 11;57(11):2078–82.

72.   Zhu K, Hilten JJ van, Putter H, Marinus J. Risk factors for hallucinations in Parkinson's disease: Results from a large prospective cohort study. Movement Disorders. 2013;28(6):755–62.